# HEXIM1

## Overview
HEXIM1 is a gene that encodes the HEXIM P-TEFb complex subunit 1, a regulatory protein involved in the modulation of transcription elongation. The protein is primarily known for its role in inhibiting the positive transcription elongation factor b (P-TEFb), a kinase complex essential for the phosphorylation of the RNA polymerase II C-terminal domain, thereby controlling transcriptional elongation (Yik2004A). HEXIM1 achieves this by forming a complex with 7SK small nuclear RNA (snRNA), sequestering P-TEFb into an inactive state (Zhou2006The). Beyond its role in transcription regulation, HEXIM1 interacts with nuclear hormone receptors, such as estrogen receptor alpha, influencing their transcriptional activities (Ogba2008HEXIM1). The protein's structure includes an arginine-rich motif crucial for RNA binding and a coiled-coil domain necessary for dimerization, which are vital for its function and interactions (Schönichen2010A; MartinezZapien2015Intermolecular). HEXIM1's expression and function have significant implications in cellular growth, differentiation, and cancer, where it acts as a tumor suppressor in certain contexts (Zhou2006The; Tan2016Stress).

## Structure
The human HEXIM1 protein is composed of 359 amino acids and features a significant unstructured region spanning residues 1-273 (MartinezZapien2015Intermolecular). Within this region, an Arginine Rich Motif (ARM) located at residues 149-179 is crucial for binding to 7SK RNA. This ARM is similar to the RNA-binding motif found in the Tat protein but is notably longer (Lebars2010HEXIM1; MartinezZapien2015Intermolecular). The ARM is typically unstructured in solution but folds upon RNA binding, interacting with the major groove of the RNA A-helix (MartinezZapien2015Intermolecular).

HEXIM1 also contains a coiled-coil domain at its C-terminus, which is essential for dimerization. This domain is divided into two segments: a weaker upstream helix (α2, residues 284-313) and a more stable downstream helix (α3, residues 319-348) (Schönichen2010A; MartinezZapien2015Intermolecular). The coiled-coil structure is characterized by a repeating heptad pattern, with nonpolar residues forming the oligomerization interface and polar residues guiding specificity (Schönichen2010A). A 'stammer' motif within this domain increases flexibility, which is necessary for binding to Cyclin T1 (Schönichen2010A).

HEXIM1 forms a dimer in cells, and this dimeric structure is involved in binding to both 7SK RNA and Cyclin T1, with a 1:2 stoichiometry for Cyclin T1 binding (Schönichen2010A; Pham2022A). The protein can undergo post-translational modifications such as phosphorylation, which may influence its activity and interactions (Lebars2010HEXIM1). Splice variant isoforms of HEXIM1 may exist, contributing to its functional diversity (Lebars2010HEXIM1).

## Function
HEXIM1 is a crucial regulator of transcription elongation in healthy human cells. It functions primarily by inhibiting the activity of the positive transcription elongation factor b (P-TEFb), which is essential for the phosphorylation of the RNA polymerase II C-terminal domain, a key step in transcriptional elongation (Yik2004A). HEXIM1 achieves this inhibition by forming a complex with 7SK small nuclear RNA (snRNA), sequestering P-TEFb into an inactive state, thereby controlling the nuclear levels of active P-TEFb and preventing excessive transcriptional activity (Zhou2006The).

HEXIM1 also interacts with nuclear hormone receptors, such as estrogen receptor alpha (ERα) and glucocorticoid receptor (GR), modulating their transcriptional activities. It inhibits the interaction between ERα and CycT1, preventing the recruitment of CycT1 and the binding of ERα to promoters, thus repressing ERα-mediated transactivation (Zhou2006The; Ogba2008HEXIM1). This regulation is significant in maintaining cellular homeostasis and allows for rapid response to environmental stimuli by releasing active P-TEFb when needed (Zhou2006The).

In terms of cellular outcomes, HEXIM1 plays a role in growth regulation and differentiation. Its expression is elevated in cells induced to differentiate, and it has antigrowth effects in various cell types, including cardiac myocytes and breast epithelial cells (Zhou2006The).

## Clinical Significance
Alterations in HEXIM1 expression or mutations in the gene have significant clinical implications, particularly in cancer. In breast cancer, HEXIM1 modulates the expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF-1α), which are crucial for angiogenesis. Mutations in HEXIM1, such as the HEXIM1 1-312 variant, lead to increased VEGF expression and tumor vascularization, suggesting a role in enhancing tumorigenesis and angiogenesis (Ogba2010HEXIM1). In triple-negative breast cancer (TNBC), downregulation of HEXIM1 results in the retention of active P-TEFb, promoting cancer progression and increasing sensitivity to Hsp90 inhibitors, which are being explored as therapeutic options (Shao2020HEXIM1).

In melanoma, HEXIM1 acts as a tumor suppressor. Its expression is significantly downregulated, not due to mutations but likely through epigenetic silencing. This downregulation contributes to melanoma progression, and restoring HEXIM1 expression can suppress tumor onset (Tan2016Stress). These findings highlight HEXIM1's potential as a therapeutic target in various cancers, where its altered expression or function can significantly impact disease progression and treatment response.

## Interactions
HEXIM1 interacts with several proteins and nucleic acids, primarily through its role in the regulation of transcription elongation by RNA polymerase II. It forms a complex with the positive transcription elongation factor b (P-TEFb), which consists of CDK9 and cyclin T, and the 7SK small nuclear RNA (snRNA). This complex inhibits the kinase activity of P-TEFb, thereby regulating transcription (Barboric2005Interplay; Michels2004Binding).

The interaction between HEXIM1 and 7SK snRNA is facilitated by an arginine-rich motif (ARM) within HEXIM1, which is crucial for binding to 7SK snRNA and P-TEFb. This binding is necessary for the inactivation of P-TEFb (Yik2004A; Barboric2005Interplay). The ARM is similar to RNA-binding motifs found in viral proteins and folds upon binding RNA, involving salt bridges and specific recognition modes like hydrogen bonding (MartinezZapien2015Intermolecular).

HEXIM1 also contains acidic regions that may bind to basic residues of the ARM, potentially creating a self-inhibitory conformation. Upon RNA binding, these acidic residues may play roles in cyclin binding or kinase inhibition (MartinezZapien2015Intermolecular). The interaction of HEXIM1 with 7SK RNA is essential for the stable formation of the P-TEFb/HEXIM1/7SK complex, which can be recapitulated in vitro using purified recombinant components (Michels2004Binding).


## References


[1. (Lebars2010HEXIM1) Isabelle Lebars, D. Martinez-Zapien, A. Durand, J. Coutant, B. Kieffer, and Anne-Catherine Dock-Bregeon. Hexim1 targets a repeated gauc motif in the riboregulator of transcription 7sk and promotes base pair rearrangements. Nucleic Acids Research, 38(21):7749–7763, July 2010. URL: http://dx.doi.org/10.1093/nar/gkq660, doi:10.1093/nar/gkq660. This article has 40 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkq660)

[2. (MartinezZapien2015Intermolecular) Denise Martinez-Zapien, Jean-Michel Saliou, Xiao Han, Cedric Atmanene, Florence Proux, Sarah Cianférani, and Anne-Catherine Dock-Bregeon. Intermolecular recognition of the non-coding rna 7sk and hexim protein in perspective. Biochimie, 117:63–71, October 2015. URL: http://dx.doi.org/10.1016/j.biochi.2015.03.020, doi:10.1016/j.biochi.2015.03.020. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.biochi.2015.03.020)

[3. (Zhou2006The) Qiang Zhou and Jasper H. N. Yik. The yin and yang of p-tefb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiology and Molecular Biology Reviews, 70(3):646–659, September 2006. URL: http://dx.doi.org/10.1128/mmbr.00011-06, doi:10.1128/mmbr.00011-06. This article has 223 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mmbr.00011-06)

[4. (Pham2022A) Vincent V. Pham, Michael Gao, Jennifer L. Meagher, Janet L. Smith, and Victoria M. D’Souza. A structure-based mechanism for displacement of the hexim adapter from 7sk small nuclear rna. Communications Biology, August 2022. URL: http://dx.doi.org/10.1038/s42003-022-03734-w, doi:10.1038/s42003-022-03734-w. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-022-03734-w)

[5. (Ogba2010HEXIM1) N Ogba, Y Q Doughman, L J Chaplin, Y Hu, M Gargesha, M Watanabe, and M M Montano. Hexim1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland. Oncogene, 29(25):3639–3649, May 2010. URL: http://dx.doi.org/10.1038/onc.2010.110, doi:10.1038/onc.2010.110. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2010.110)

[6. (Barboric2005Interplay) Matjaz Barboric, Jiří Kohoutek, Jason P Price, Dalibor Blazek, David H Price, and B Matija Peterlin. Interplay between 7sk snrna and oppositely charged regions in hexim1 direct the inhibition of p-tefb. The EMBO Journal, 24(24):4291–4303, December 2005. URL: http://dx.doi.org/10.1038/sj.emboj.7600883, doi:10.1038/sj.emboj.7600883. This article has 83 citations.](https://doi.org/10.1038/sj.emboj.7600883)

[7. (Michels2004Binding) Annemieke A Michels, Alessandro Fraldi, Qintong Li, Todd E Adamson, François Bonnet, Van Trung Nguyen, Stanley C Sedore, Jason P Price, David H Price, Luigi Lania, and Olivier Bensaude. Binding of the 7sk snrna turns the hexim1 protein into a p-tefb (cdk9/cyclin t) inhibitor. The EMBO Journal, 23(13):2608–2619, June 2004. URL: http://dx.doi.org/10.1038/sj.emboj.7600275, doi:10.1038/sj.emboj.7600275. This article has 245 citations.](https://doi.org/10.1038/sj.emboj.7600275)

[8. (Tan2016Stress) Justin L. Tan, Rachel D. Fogley, Ryan A. Flynn, Julien Ablain, Song Yang, Violaine Saint-André, Zi Peng Fan, Brian T. Do, Alvaro C. Laga, Koh Fujinaga, Cristina Santoriello, Celeste B. Greer, Yoon Jung Kim, John G. Clohessy, Anne Bothmer, Nicole Pandell, Serine Avagyan, John E. Brogie, Ellen van Rooijen, Elliott J. Hagedorn, Ng Shyh-Chang, Richard M. White, David H. Price, Pier Paolo Pandolfi, B. Matija Peterlin, Yi Zhou, Tae Hoon Kim, John M. Asara, Howard Y. Chang, Richard A. Young, and Leonard I. Zon. Stress from nucleotide depletion activates the transcriptional regulator hexim1 to suppress melanoma. Molecular Cell, 62(1):34–46, April 2016. URL: http://dx.doi.org/10.1016/j.molcel.2016.03.013, doi:10.1016/j.molcel.2016.03.013. This article has 74 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.molcel.2016.03.013)

[9. (Ogba2008HEXIM1) Ndiya Ogba, Laura J. Chaplin, Yong Qiu Doughman, Koh Fujinaga, and Monica M. Montano. Hexim1 regulates 17β-estradiol/estrogen receptor-α–mediated expression of cyclin d1 in mammary cells via modulation of p-tefb. Cancer Research, 68(17):7015–7024, August 2008. URL: http://dx.doi.org/10.1158/0008-5472.CAN-08-0814, doi:10.1158/0008-5472.can-08-0814. This article has 41 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-08-0814)

[10. (Yik2004A) Jasper H. N. Yik, Ruichuan Chen, Andrea C. Pezda, Craig S. Samford, and Qiang Zhou. A human immunodeficiency virus type 1 tat-like arginine-rich rna-binding domain is essential for hexim1 to inhibit rna polymerase ii transcription through 7sk snrna-mediated inactivation of p-tefb. Molecular and Cellular Biology, 24(12):5094–5105, June 2004. URL: http://dx.doi.org/10.1128/MCB.24.12.5094-5105.2004, doi:10.1128/mcb.24.12.5094-5105.2004. This article has 146 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.24.12.5094-5105.2004)

[11. (Schönichen2010A) André Schönichen, Janna M. Bigalke, Claus Urbanke, Stephan Grzesiek, Sonja A. Dames, and Matthias Geyer. A flexible bipartite coiled coil structure is required for the interaction of hexim1 with the p-tefb subunit cyclin t1. Biochemistry, 49(14):3083–3091, March 2010. URL: http://dx.doi.org/10.1021/bi902072f, doi:10.1021/bi902072f. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi902072f)

[12. (Shao2020HEXIM1) Hengyi Shao, Qingwei Zhu, Huasong Lu, Amanda Chang, Carol Gao, Qiang Zhou, and Kunxin Luo. Hexim1 controls p-tefb processing and regulates drug sensitivity in triple-negative breast cancer. Molecular Biology of the Cell, 31(17):1867–1878, August 2020. URL: http://dx.doi.org/10.1091/mbc.e19-12-0704, doi:10.1091/mbc.e19-12-0704. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.e19-12-0704)